Get the app
US › Healthcare

Neuropace Inc (NPCE)

US · Healthcare · Medical Devices

$14.15+0.35%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$22.8M
Revenue YoY
-3.0%
Net profit
$-6.2M
EPS
$-0.18
EPS estimate
$-0.19
Net margin
-27.2%

EPS came in at -0.18 against a street estimate of -0.19 — a beat of 5.3%.

Key statistics

Market cap
$481.9M
Forward P/E
156.2
P/B
40.58
Book value
$0.35
EPS (TTM)
$-0.47
52-week high
$19.60
52-week low
$9.22
50-day MA
$14.96
200-day MA
$15.49
Beta
1.95

Analyst view

Analysts rate Neuropace Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $20.22.

Shareholding

Insiders
4.47%
Institutions
97.30%

Largest institutional holders

FundStake
Polar Capital Holdings PLC9.61%
Soleus Capital Management, L.P.8.48%
First Light Asset Management, LLC8.34%
Morgan Stanley - Brokerage Accounts7.48%
BlackRock Inc6.84%
Orbimed Advisors LLC6.11%
Driehaus Capital Management LLC4.23%
Vanguard Capital Management, LLC3.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neuropace Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.